TY - JOUR AU - Chandarlapaty, S. AU - Chen, D. AU - He, W. AU - Sung, P. AU - Samoila, A. AU - You, D. PY - 2016 DA - 2016// TI - Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial JO - JAMA Oncol VL - 2 UR - https://doi.org/10.1001/jamaoncol.2016.1279 DO - 10.1001/jamaoncol.2016.1279 ID - Chandarlapaty2016 ER - TY - JOUR AU - Clatot, F. AU - Perdrix, A. AU - Augusto, L. AU - Beaussire, L. AU - Delacour, J. AU - Calbrix, C. PY - 2016 DA - 2016// TI - Kinetics, prognostic and predictive values of ESR1 circulating mutations in metastatic breast cancer patients progressing on aromatase inhibitor JO - Oncotarget VL - 7 UR - https://doi.org/10.18632/oncotarget.12950 DO - 10.18632/oncotarget.12950 ID - Clatot2016 ER - TY - JOUR AU - Fribbens, C. AU - O’Leary, B. AU - Kilburn, L. AU - Hrebien, S. AU - Garcia-Murillas, I. AU - Beaney, M. PY - 2016 DA - 2016// TI - Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer JO - J Clin Oncol VL - 34 UR - https://doi.org/10.1200/JCO.2016.67.3061 DO - 10.1200/JCO.2016.67.3061 ID - Fribbens2016 ER - TY - JOUR AU - Takeshita, T. AU - Yamamoto, Y. AU - Yamamoto-Ibusuki, M. AU - Inao, T. AU - Sueta, A. AU - Fujiwara, S. PY - 2015 DA - 2015// TI - Droplet digital polymerase chain reaction assay for screening of ESR1 mutations in 325 breast cancer specimens JO - Transl Res VL - 166 UR - https://doi.org/10.1016/j.trsl.2015.09.003 DO - 10.1016/j.trsl.2015.09.003 ID - Takeshita2015 ER - TY - JOUR AU - Segal, C. V. AU - Dowsett, M. PY - 2014 DA - 2014// TI - Estrogen receptor mutations in breast cancer--new focus on an old target JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-14-0067 DO - 10.1158/1078-0432.CCR-14-0067 ID - Segal2014 ER - TY - JOUR AU - Schiavon, G. AU - Hrebien, S. AU - Garcia-Murillas, I. AU - Cutts, R. J. AU - Pearson, A. AU - Tarazona, N. PY - 2015 DA - 2015// TI - Analysis of ESR1 mutation in circulating tumor DNA demonstrates evolution during therapy for metastatic breast cancer JO - Sci Transl Med VL - 7 UR - https://doi.org/10.1126/scitranslmed.aac7551 DO - 10.1126/scitranslmed.aac7551 ID - Schiavon2015 ER - TY - JOUR AU - Sefrioui, D. AU - Perdrix, A. AU - Sarafan-Vasseur, N. AU - Dolfus, C. AU - Dujon, A. AU - Picquenot, J. -. M. PY - 2015 DA - 2015// TI - Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer JO - Int J Cancer VL - 137 UR - https://doi.org/10.1002/ijc.29612 DO - 10.1002/ijc.29612 ID - Sefrioui2015 ER - TY - JOUR AU - Senkus, E. AU - Kyriakides, S. AU - Ohno, S. AU - Penault-Llorca, F. AU - Poortmans, P. AU - Rutgers, E. PY - 2015 DA - 2015// TI - Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up JO - Ann Oncol VL - 26 UR - https://doi.org/10.1093/annonc/mdv298 DO - 10.1093/annonc/mdv298 ID - Senkus2015 ER - TY - STD TI - Fribbens C, Garcia Murillas I, Beaney M, Hrebien S, O’Leary B, Kilburn L, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018;29(1):145–53. https://doi.org/10.1093/annonc/mdx483. ID - ref9 ER - TY - JOUR AU - Spoerke, J. M. AU - Gendreau, S. AU - Walter, K. AU - Qiu, J. AU - Wilson, T. R. AU - Savage, H. PY - 2016 DA - 2016// TI - Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant JO - Nat Commun VL - 7 UR - https://doi.org/10.1038/ncomms11579 DO - 10.1038/ncomms11579 ID - Spoerke2016 ER - TY - JOUR AU - Wan, J. C. M. AU - Massie, C. AU - Garcia-Corbacho, J. AU - Mouliere, F. AU - Brenton, J. D. AU - Caldas, C. PY - 2017 DA - 2017// TI - Liquid biopsies come of age: towards implementation of circulating tumour DNA JO - Nat Rev Cancer VL - 17 UR - https://doi.org/10.1038/nrc.2017.7 DO - 10.1038/nrc.2017.7 ID - Wan2017 ER -